Related Experiment Video
Updated: Jun 2, 2026
07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.1K
PRECISE: A Prognostic Thyrocyte-Derived Gene Signature for Papillary Thyroid Carcinoma
Sophie Li1, Chia-Chin Wu1, Vicente R Marczyk2
1Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Summary
A new thyroid cancer gene signature, PRECISE, shows strong prognostic value. This discovery improves risk stratification for papillary thyroid carcinoma (PTC) patients, aiding in better treatment decisions.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Papillary thyroid carcinoma (PTC) displays variable behavior, necessitating advanced biomarkers for accurate risk assessment.
- Current risk stratification methods require enhancement to effectively manage PTC heterogeneity.
Purpose of the Study:
- To develop and validate a novel thyrocyte-derived gene signature, Prognostic RNA Expression Cell-specific Integrated SignaturE (PRECISE), for prognostic evaluation in PTC.
- To assess the independent prognostic utility of PRECISE across multiple patient cohorts.
Main Methods:
- PRECISE was developed using single-cell and single-nucleus RNA sequencing (RNAseq) data from PTC tumors and normal thyroid samples.
- Prognostic significance was evaluated using bulk RNAseq in a discovery cohort and validated in two independent cohorts (VUMC, TCGA).
- Associations with progression-free survival (PFS) and disease-specific survival (DSS) were analyzed using multivariate Cox models.
Main Results:
- PRECISE consists of 41 epithelial genes downregulated in PTC.
- Higher PRECISE scores were significantly linked to shorter PFS across all three cohorts, even after TNM stage adjustment.
- PRECISE demonstrated significant associations with DSS and improved predictive performance beyond traditional staging models.
Conclusions:
- The PRECISE gene signature possesses independent prognostic value in papillary thyroid carcinoma.
- PRECISE offers a promising tool for enhancing risk stratification and predicting outcomes in PTC patients.
